Bright Minds Biosciences (TSE:DRUG) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Bright Minds Biosciences has announced promising preclinical results for its compound BMB-201, which showed similar pain relief efficacy to morphine without the associated dependency risks. This development is a significant step in providing non-opioid alternatives for neuropathic pain management, with plans to advance into clinical trials.
For further insights into TSE:DRUG stock, check out TipRanks’ Stock Analysis page.
